This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vaccine Hopes Rise Again: 4 Stocks to Watch
by Ritujay Ghosh
The United States is ensuring adequate doses of the Coronavirus vaccine once it is developed. Some companies leading the race are Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and Sanofi (SNY).
Dow Jones Tops 29,000: Will ETFs & Stocks Rally in September?
by Sanghamitra Saha
The Dow jumped above 29,000 for the first time since February on Sep 2 on low rates and vaccine hopes.
Novavax to Supply Coronavirus Vaccine to Canadian Government
by Zacks Equity Research
Novavax (NVAX) signs a contract with the Government of Canada for supplying up to 76 million doses of its COVID-19 vaccine NVX-CoV2373, if approved.
Top ETF Stories of the Best August in 34 Years
by Sanghamitra Saha
Wall Street hit several fresh highs in August as investors rotated into the beaten-down segments of the year ??? cyclicals.
AstraZeneca Begins Coronavirus Vaccine US Phase III Study
by Zacks Equity Research
AstraZeneca's(AZN) phase III study to enroll 30,000 adult participants and assess the safety, efficacy and immunogenicity of its COVID-19 vaccine candidate, AZD1222.
Moderna May Supply 40M Coronavirus Vaccine Doses to Japan
by Zacks Equity Research
Moderna (MRNA) is negotiating a deal with Japanese authorities for supply of its coronavirus vaccine in Japan, following a potential approval.
Moderna ETFs to Gain on New Positive COVID-19 Vaccine Data
by Sweta Jaiswal, FRM
Per the latest data from an early stage clinical trial, Moderna's experimental coronavirus vaccine is successfully producing neutralizing antibodies and T-cells in older adults.
VBI Vaccines Up on Coronavirus Vaccine Candidates Selection
by Zacks Equity Research
VBI Vaccines (VBIV) selects two coronavirus vaccine candidates for clinical-stage development based on encouraging pre-clinical data.
Invest in Hottest IPOs With These ETFs
by Neena Mishra
The IPO market remains very healthy despite the pandemic.
Biotech Stock Roundup: BMY to Buy Forbius, BMRN Gets CRL & Other Updates
by Zacks Equity Research
The biotech sector remains in focus with drug approvals, and regulatory and other pipeline updates.
Stock Market News for Aug 26, 2020
by Zacks Equity Research
Benchmarks closed higher on Wednesday fueled by a rally in technology shares amid positive coronavirus vaccine trail news.
Moderna Stock Surges 260% YTD on Coronavirus Vaccine Progress
by Zacks Equity Research
Moderna (MRNA) is making significant progress in development of coronavirus vaccine. The vaccine is currently in phase III study.
AstraZeneca Begins Coronavirus Antibody Combo Phase I Study
by Zacks Equity Research
AstraZeneca's (AZN) AZD7442 is a combination of two coronavirus-neutralizing monoclonal antibodies, AZD8895 and AZD1061.
5 Sectors Set to Boom on Coronavirus Vaccine Optimism: Top Picks
by Sweta Killa
While the prospect of a COVID-19 treatment will lead to broad-based gains, some investing areas are expected to benefit the most.
Novavax Begins Enrollment in Phase II Coronavirus Vaccine Study
by Zacks Equity Research
Novavax (NVAX) starts enrolling in the phase II portion of its COVID-19 vaccine study, which is testing the immunogenicity and safety of its candidate NVX-CoV2373 in the United States and Australia.
AstraZeneca Coronavirus Vaccine May Get FDA's Emergency Tag
by Zacks Equity Research
AstraZeneca's (AZN)/Oxford's AZD1222 is in phase II/III study in the UK, Brazil and South Africa with a late-stage study due to start soon in the United States with 30,000 participants.
Regeneron Gains on Coronavirus Treatment Development Efforts
by Zacks Equity Research
Regeneron's (REGN) shares grow year to date owing to focus on developing a treatment for the novel coronavirus.
Novavax Begins Phase IIb Coronavirus Vaccine Study in South Africa
by Zacks Equity Research
Novavax (NVAX) starts a phase IIb study in South Africa to evaluate the efficacy of its COVID-19 vaccine candidate NVX-CoV2373. Shares rise following this development.
AstraZeneca (AZN) to Supply Coronavirus Vaccine in Europe
by Zacks Equity Research
AstraZeneca (AZN) closes a deal with the European Commission for supplying at least 400 million doses of its COVID-19 vaccine, AZD1222, if approved.
Novavax (NVAX) to Supply Coronavirus Vaccine to UK Government
by Zacks Equity Research
Novavax (NVAX) enters an agreement to provide the UK government with 60 million doses of its COVID-19 vaccine, NVX-CoV2373, if approved.
Moderna ETFs to Shine on U.S. Contracts for Coronavirus Vaccine
by Sweta Jaiswal, FRM
Moderna has inked a $1.5-billion coronavirus vaccine supply agreement with the U.S. government.
Tivity, GrafTech, Moderna, Glaxo and AstraZeneca as Zacks Bull and Bear of the Day
by Zacks Equity Research
Tivity, GrafTech, Moderna, Glaxo and AstraZeneca as Zacks Bull and Bear of the Day
Implied Volatility Surging for Moderna (MRNA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
US Continues to Secure Coronavirus Vaccines: 4 Stocks to Watch
by Ritujay Ghosh
The deal with Moderna yet again renewed hopes among millions about a possible vaccine by the end of this year.
Moderna Up on $1.5B Federal Funding for Coronavirus Vaccine
by Zacks Equity Research
Moderna (MRNA) inks a deal with the U.S. government for supplying 100 million doses of mRNA-1273, its vaccine against COVID-19. Shares rise in pre-market trading.